The Evaluation of Tomographic 3D Ultrasound for the Assessment of Vascular Pathology
NCT ID: NCT04318171
Last Updated: 2023-01-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
75 participants
OBSERVATIONAL
2021-07-01
2023-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A new sensor which provides 3D images is newly designed. It will be used in this study to find out whether it can change the future of vascular imaging or not.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Risk Assessment of Carotid Plaques Using 3D Contrast-Enhanced Ultrasound
NCT04643431
Carotid Artery Plaque Vulnerability Assessment Using Ultrafast Ultrasound Techniques
NCT05218421
Advanced Ultrasound Methods in the Assessment of Carotid Plaque Instability
NCT03672955
Carotid Ultrasound Sub-Study of the Familial Atherosclerosis Study-observational Study
NCT00976014
Contrast Enhanced SWI for Carotid Plaque Imaging
NCT02749916
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
DUS provides valuable information in diagnosing vascular disease due to its ability to detect flow motion within a vessel. It is, therefore, able to define whether the vessel being scanned is narrowed, diseased or blocked.
3D Ultrasound: 3D ultrasound provides images from different angles for better detection of structures being assessed. Therefore, the accuracy of the vessels and anatomical structures around is high. 3D Volume now becomes available and can be calculated and potentially benefits patients by detecting and defining those who are at risk of vascular disease.
There are three types of 3D ultrasound which are:
* Mechanical 3D
* 3D and 4D matrix scanning.
* Freehand 3D sensor. (Will be used in this project).
The targeted structures are:
Carotid arteries. Peripheral arteries including upper and lower limbs. Arteriovenous Fistula. Vein mapping pre coronary artery bypass graft (CABG).
Carotid Plaque Volume:
In 2009, a joint working coordinated efforts between the United Kingdom (UK) Vascular Societies concurred that the North American Symptomatic Carotid Endarterectomy Trial (NASCET) method for evaluating and grading carotid artery disease should be utilised in the UK.
In addition to current criteria used for grading carotid stenosis, Carotid plaque volume (CPV) is a measurement that may be a better predictive of embolic risk and stroke. CPV may be used to determine whether the patients with \<70% stenosis and large plaque volume are at risk as other patients who present with \>70% focal and short stenosis. A significant benefit of measuring Carotid plaque volume is observing the progression or regression of the area affected. This can be done clinically and in a quite relevant time frame.
Peripheral arterial disease (PAD):
20% of patients aged \< 60 are likely to suffer from PAD including those present with intermittent claudication and also patients with critical limb ischemia (5-10%) of cases).
Uncontrolled diabetes mellitus can lead to the diabetic foot which can cause further complications such as infection, ulcer and neuropathy. DUS plays a vital role in diagnosing PAD particularly for those who are unable to be investigated by other modalities. Until now, there has been no work or research done on assessing PAD plaque volume. Investigating PAD using 3D may give an accurate diagnosis and provide more image details which can lead to a better treatment plan either by using endovascular or surgical procedures.
Arteriovenous Fistula AVF:
DUS pre and post AVF is considered the golden method of mapping and routinely assessing AVF. Renal association guidelines has stated that patients should undergo DUS for mapping in particular for those who have had previous central vein catheterisation procedures.
DUS mapping has been proven that it can positively reduce surgical complications including immediate failure. DUS also provides valuable details on AVF function and complications post creation based on current criteria including inflow and outflow volume rate. In this research, 3D US will be used to determine whether it can provide better result in compare to DUS which is currently the most widely used imaging modality.
Vein mapping:
DUS is currently used as a gold standard for vein mapping prior CABG and provides sufficient details about saphenous veins patency and suitability for using them as autogenous graft 195. 3D US may provide better image quality in demonstrating small vein branches and may improve surgical outcomes by providing more details prior to harvesting. It may also provide better details for surgeons on where to make an incision and defining the best segment of the vain is much appropriate.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Carotid arteries.
No intervention is required. Routine Doppler assessment + 3D scan immediately afterwards.
3D Imaging.
When the normal Doppler assessment is done following nationally approved protocol for scanning Carotid arteries, lower and upper limb arteries, AVF and Vein mapping. PIUR tUS infinity system 3D Bluetooth motion sensor which is linked to video transmission box will be used to scan the patient's common carotid artery (CCA), internal carotid artery (ICA) and external carotid artery (ECA) in transverse view to obtain the following measurements:
* Plaque volume where detectable.
* Max area stenosis.
* Volumetric stenosis.
* Measured length.
* 3D GSM. The entire assessment should not take more than 45 minutes.
Peripheral arteries.
No intervention is required. Routine Doppler assessment + 3D scan immediately afterwards.
3D Imaging.
When the normal Doppler assessment is done following nationally approved protocol for scanning Carotid arteries, lower and upper limb arteries, AVF and Vein mapping. PIUR tUS infinity system 3D Bluetooth motion sensor which is linked to video transmission box will be used to scan the patient's common carotid artery (CCA), internal carotid artery (ICA) and external carotid artery (ECA) in transverse view to obtain the following measurements:
* Plaque volume where detectable.
* Max area stenosis.
* Volumetric stenosis.
* Measured length.
* 3D GSM. The entire assessment should not take more than 45 minutes.
AVF.
No intervention is required. Routine Doppler assessment + 3D scan immediately afterwards.
3D Imaging.
When the normal Doppler assessment is done following nationally approved protocol for scanning Carotid arteries, lower and upper limb arteries, AVF and Vein mapping. PIUR tUS infinity system 3D Bluetooth motion sensor which is linked to video transmission box will be used to scan the patient's common carotid artery (CCA), internal carotid artery (ICA) and external carotid artery (ECA) in transverse view to obtain the following measurements:
* Plaque volume where detectable.
* Max area stenosis.
* Volumetric stenosis.
* Measured length.
* 3D GSM. The entire assessment should not take more than 45 minutes.
Vein mapping
No intervention is required. Routine Doppler assessment + 3D scan immediately afterwards.
3D Imaging.
When the normal Doppler assessment is done following nationally approved protocol for scanning Carotid arteries, lower and upper limb arteries, AVF and Vein mapping. PIUR tUS infinity system 3D Bluetooth motion sensor which is linked to video transmission box will be used to scan the patient's common carotid artery (CCA), internal carotid artery (ICA) and external carotid artery (ECA) in transverse view to obtain the following measurements:
* Plaque volume where detectable.
* Max area stenosis.
* Volumetric stenosis.
* Measured length.
* 3D GSM. The entire assessment should not take more than 45 minutes.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
3D Imaging.
When the normal Doppler assessment is done following nationally approved protocol for scanning Carotid arteries, lower and upper limb arteries, AVF and Vein mapping. PIUR tUS infinity system 3D Bluetooth motion sensor which is linked to video transmission box will be used to scan the patient's common carotid artery (CCA), internal carotid artery (ICA) and external carotid artery (ECA) in transverse view to obtain the following measurements:
* Plaque volume where detectable.
* Max area stenosis.
* Volumetric stenosis.
* Measured length.
* 3D GSM. The entire assessment should not take more than 45 minutes.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male / Female.
Exclusion Criteria
* Patient with congenital vascular abnormalities/syndromes.
* Pregnant patients will not be recruited in this study. Patient's pregnancy status will be assessed on initial enrollment to exclude them from the study.
* Those unable to provide consent.
* Anyone who is taking part in any other research.
* Potential participants who might not adequately understand verbal explanations or written information given in English, or who have special communication needs.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Imperial College London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Imperial College London
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20HH5799
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.